Management of Diabetic Ketoacidosis in ESRD Patients

Initial Assessment and Diagnosis

• The American Diabetes Association recommends DKA diagnostic criteria for ESRD patients, including blood glucose >250 mg/dL, arterial pH <7.3, bicarbonate <15 mEq/L, and moderate ketonemia or ketonuria 2
• Direct measurement of β-hydroxybutyrate in blood is preferred for monitoring DKA resolution in ESRD patients, according to the American Association of Clinical Endocrinologists 3

Insulin Therapy

• The American College of Clinical Endocrinologists recommends continuous intravenous insulin as the standard of care for critically ill ESRD patients with DKA 1
• More frequent glucose monitoring (every 1-2 hours) is recommended to prevent hypoglycemia, as suggested by the American Diabetes Association 1

Electrolyte Management

• The National Kidney Foundation recommends potassium replacement be approached with extreme caution in ESRD patients, as they are prone to hyperkalemia 2
• Bicarbonate administration is generally not recommended, consistent with standard DKA management, according to the American Diabetes Association 1 and the Endocrine Society 4

Transition from IV to Subcutaneous Insulin

• The American Association of Clinical Endocrinologists recommends administering basal insulin 2-4 hours before stopping the IV insulin to prevent recurrence of ketoacidosis 1
• For uncomplicated cases, subcutaneous insulin regimens may be used instead of IV insulin, which can be safer and more cost-effective, as suggested by the American College of Clinical Endocrinologists 1

Monitoring for Resolution

• Treatment success is indicated by resolution of acidosis (pH >7.3), serum bicarbonate ≥18 mEq/L, anion gap ≤12 mEq/L, and improvement in clinical symptoms, according to the American Association of Clinical Endocrinologists 3

Discharge Planning

• The American Diabetes Association recommends structured discharge planning, beginning at admission and updated as patient needs change 4
• Ensure clear communication about medication changes, follow-up needs, and sick-day management to outpatient providers, as suggested by the American College of Clinical Endocrinologists 1